Paclitaxel trevatide (formerly known as ANG 1005 or GRN 1005) is a paclitaxel-peptide drug conjugate, where three paclitaxel molecules linked by a cleavable succinyl ester linkage to a brain peptide vector, Angiopep-2. Paclitaxel trevatide is an oncology product to leverage the low-density lipoprotein receptor-related protein 1 (LRP-1) pathway to cross the blood-brain barrier (BBB) and enter cancer cells. This drug successfully completed phase II clinical trials in breast cancer patients with recurrent brain metastases and in patients with high-grade glioma. 30-May-2014 Angiochem, the company that developed this drug, announced that the Food & Drug Association (FDA) had granted both orphan drug and fast track designation to paclitaxel trevatide for the treatment of glioblastoma multiforme (GBM). In addition, paclitaxel trevatide is going to be involved in phase III clinical trial to see if this drug can prolong survival compared to a Physician Best Choice control in HER2-negative breast cancer patients with the newly diagnosed leptomeningeal disease and previously treated brain metastases.